The European Commission approved Dupixent (dupilumab) for use in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitric oxide, who are inadequately controlled with high dose inhaled corticosteroid plus another medicinal product for maintenance treatment.

U.S. Food and Drug Administration staff reviewers raised doubts over the effectiveness of GlaxoSmithKline Plc’s drug Nucala in treating a disease that limits airflow to the lungs.

Teva Pharmaceutical Industries said two late-stage studies testing the company’s treatment for asthma did not meet their main goals.

The first new asthma pill in decades has produced promising results in a small study, potentially paving the way for another treatment option by the end of the decade.